![Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2021/02/shutterstock_1224254950-1.jpg)
Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology
![Novo Nordisk wins FDA approval for higher-dose Ozempic for adults with type 2 diabetes - Drug Discovery and Development Novo Nordisk wins FDA approval for higher-dose Ozempic for adults with type 2 diabetes - Drug Discovery and Development](https://www.drugdiscoverytrends.com/wp-content/uploads/2022/03/ozempic-pen.png)
Novo Nordisk wins FDA approval for higher-dose Ozempic for adults with type 2 diabetes - Drug Discovery and Development
![Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg Demonstration Pen (0.25 mg, 0.5 mg) | novoMEDLINK™ Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg Demonstration Pen (0.25 mg, 0.5 mg) | novoMEDLINK™](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/diabetes/patient/product/library/images/ozempic-demo-pen.png)
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg Demonstration Pen (0.25 mg, 0.5 mg) | novoMEDLINK™
![Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus](http://pharmtechfocus.com/wp-content/uploads/2022/03/Novo-Nordisk-Receives-Fda-Approval-of-Higher-dose-Ozempic%C2%AE-2-Mg-Providing-Increased-Glycemic-Control-for-Adults-With-Type-2-Diabetes-1.jpg)
Novo Nordisk Receives Fda Approval of Higher-dose Ozempic® 2 Mg Providing Increased Glycemic Control for Adults With Type 2 Diabetes - PharmTech Focus
![Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes – PharmaLive Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes – PharmaLive](https://www.pharmalive.com/wp-content/uploads/2020/08/ozempic-1030x581.jpg)